In the field of osteoporosis,oncology, neurology,etc.
In the field of bone health, HSN promotes the implementation of the osteoporosis integrated diagnosis and treatment scheme, including promoting the registration and marketing of Bonviva® (Film-coated Tablets Ibandronic Acid) in China (currently approved for use in Hainan Boao Lecheng International Medical Tourism Pilot Zone). In April 2023, Pharmanovia & HSN kicked off “Leaping Tiger” project and HSN became the CSO of Rocaltrol® (Calcitriol Soft Capsules) in China, responsible for the national marketing and promotion of the product. At the same time, HSN promotes the integrated solutions of osteoporosis diagnosis and treatment by introducing LINGLONG® AI DXA Machine (dual energy X-ray absorptiometry).
In the field of Oncology, HSN focuses on the prevention and treatment of SREs in patients with tumor bone metastasis. HSN and Pharmanovia have established the strategic cooperation in 2018 to fully take charge of the commercialization and marketing promotion of the imported original drug Bondronat® (Sodium Ibandronate Injection, the latest generation, that is, the third generation of bisphosphonate) in China.
In the field of mental health, HSN has already made inroads into the rare disease domain. Since 2023, it has formed a strategic partnership with RareStone Group to jointly promote the commercialization of WAKIX® (Pitolisant Hydrochloride Tablets) with Citrine Medicine. HSN will focus on promoting the development of diagnosis and treatment for narcolepsy, providing effective medication for and benefiting more narcolepsy patients.
In the field of women’s health, Hosanna focuses on gynecological oncology and reproduction. Hesenna added a new indication of SREs for breast cancer patients with bone metastases for Bondronat® (Ibandronate Injection) in 2018, and will continue to introduce new drugs for the treatment of breast cancer in the future to provide more treatment options for breast cancer patients. In the area of gynecological reproduction, Hesenna plans to introduce a vaginally administered formulation of progesterone to provide a Luteal Phase Support treatment option for women undergoing ART (Assisted Reproductive Technology).
Based in China and facing the world, HSN is a pharmaceutical group that provides integrated services of Commercialization, supply chain, and brand promotion of foreign high-end patented drugs in China. An emerging strategic partner for your brand.
Copyright © 2024 – Hesenna Medicine All rights reserved.
